186 drugs to be transferred out of Guangxi medical insurance (with list)

Medical Network June 8th, 186 drugs, transferred out of Guangxi medical insuranceJune 4, Guangxi Zhuang Autonomous Region Medical Insurance Bureau issued a notice on the adjustment of the norms of "Guangxi basic medical insurance, industrial injury insurance and maternity insurance drugs catalog" noticenotice is clear:1The drugs adjusted in accordance with the provisions within the scope of payment of basic medical insurance, industrial injury insurance and maternity insurance drugs in Guangxi shall be gradually digested within three years, and the national catalogue of basic medical insurance, industrial injury insurance and maternity insurance drugs will be uniformly implemented from June 1, 2022Second, adjust the specification of some drug names, classification, dosage form and limit the scope of payment3This notice shall be implemented from June 1, 2020, and if it is inconsistent with the provisions of this notice, this notice shall prevailAccording to Cypress Blue combing, in Guangxi this adjustment norms western medicine, Traditional Chinese medicine part, 144 drugs were transferred out of the Western medicine part, 42 drugs were transferred out of the traditional Chinese medicine partIn addition, a large number of medicines have been required to implement limited payment coverage in accordance with the national 2019 drug catalogue, and a small number of drugs have been partially removed from the reimbursable dosage formThe adjusted Guangxi "Drug Catalog" includes 1645 Western medicines, 1759 Chinese traditional medicines (including 97 ethnic drugs), and 118 drugs negotiated during the agreement period (including 95 Western medicines and 23 Chinese medicines), for a total of 3522The number of drugs included in the regular access section of the 2019 edition of the National Health Insurance Directory was 2,643, including 1,322 Western medicines, 1321 traditional Chinese medicines (including 93 ethnic medicines);In April this year, the Local Supplementary Health Insurance Variety Digestion accelerated, it was revealed that the State Health Insurance Administrationthe price of medicineand thetender procurement department has issued a focus on 2020 　　Among them, on the management of the medical insurance catalog, requires all regions as soon as possible to develop a three-year digestion plan for additional varieties, by the end of June this year, the national key monitoring varieties out of the catalog, and complete the 40% of the province's supplementary varieties digestion 　　On February 5, the State Health Insurance Administration issued the "2020 Notice of The Key Points of Medical Insurance Work" that mentioned strengthening the management of the medical insurance catalogue - establishing a dynamic adjustment mechanism for the medical insurance drug catalogue, strengthening supervision and dispatching, and promoting the digestion of self-supplemented varieties in various places according to schedule 　　On August 20 last year, the State Administration of Health Insurance officially issued the 2019 edition of the National Health Insurance Directory, and at the same time proposed that: "all places should strictly implement the Drug Catalog, not to develop their own catalogs or use alternative methods to increase the list of drugs in the catalog, nor to adjust the scope of limited payment of drugs in the catalog For the original provincial drug catalogue in accordance with the provisions of the increase of Class B drugs, should be gradually digested within 3 years In the process of digestion, the provinces shall give priority to the adjustment of the scope of payment of drugs that are included in the scope of national key monitoring" 　　According to Cypress Blue understand, the local supplementary varieties transfer out of the medical insurance arrangements are as follows: 1, focus on monitoring the list of drugs to take the lead out of the medical insurance director y; the 2019 health care catalog has been officially implemented since January 1 this year According to the requirements of the National Health Insurance Administration, the provinces that docked the 2019 edition of the National Health Insurance Directory have explicitly proposed to remove state-focused surveillance drugs from the health insurance catalog 　　Many places have begun to clean up the addition of additional varieties
according to The seiber blue statistics, has Jiangxi, Shandong, Beijing, Hunan, Sichuan, Guangdong, Tianjin, Zhejiang, Anhui, Guangxi and other at least 15 provinces and cities on the local health insurance catalog addition varieties to remove clear text, 4 provinces and cities on the local health insurance supplementary varieties to give specific catalogues or guidance, many provinces and cities have published the transfer list 　　On April 22nd, Anhui Provincial Health Insurance Bureau published a draft of the draft for the digestion of the local medical insurance drug catalogue, explaining the varieties transferred from the provincial medical insurance catalogue Anhui Province has announced two specific points of time: the release of priority digested drugs in June 2020, all digestive varieties by the end of December 2020, and a specific time to withdraw from the scope of medical payments in Anhui Province During the three-year digestion period, if the relevant national policies are adjusted, they shall be implemented in accordance with the national regulations 　　It has been reported that the Jiangxi Provincial Health Insurance Bureau has established the "Jiangxi Province TransitionAl Reserve Drug Catalog", including 22 Western medicines and 46 traditional Chinese medicines beyond the "National New Edition Catalog", the retention period will be until December 31, 2020 and June 30, 2022, respectively, after the expiration of the direct removal of the health insurance directory 　　Shandong Province Medical Insurance Bureau has announced three years of gradual digestion of the varieties of medical insurance, a total of 268, of which 143 Western medicine, 125 traditional Chinese medicine 　　Hunan Provincial Health Insurance Bureau also issued a notice to determine the "digestion period of the drug part", a total of 404 varieties This part of the variety will be digested year by year in accordance with the provisions of the state, clearing out the scope of medical insurance 　　The Beijing Municipal Medical Insurance Bureau issued a notice explicitly removing drugs from the list of national medical insurance drugs and drugs under the scope of national key control of medical insurance, industrial injury insurance and maternity insurance, with a total of 352 varieties, including 281 Western and 71 traditional Chinese medicines 　　Hebei Province Medical Insurance Bureau also issued a clear, the original addition of Class B drugs, priority to transfer into the national and provincial key monitoring scope of drugs, the formation of a temporary reservation of the provincial supplementary drug catalog, the provincial medical security bureau will be gradually digested within three years There are 498 varieties in the provincial supplementary catalogue, including 286 Western medicines and 212 traditional Chinese medicines 　　For the varieties that have been transferred out of the local health insurance supplement arydirectory, it is tantamount to a direct loss of eligibility for medical insurance reimbursement With the increase of the national health insurance catalog adjustment frequency, some drugs with high price, inaccurate clinical efficacy and obvious therapeutic advantage will also face the pressure of losing medical insurance reimbursement 　　The dynamic adjustment of the medical insurance catalogue will normalize on April 29, the official website of the State Medical Security Administration issued the Interim Measures for the Administration of Drug Use in Basic Medical Insurance (Draft for Comments) for public consultation, which makes it clear that the National Medical Insurance Directory will be dynamically adjusted, in principle, once a year 　　Compared with the previous edition, the 2019 edition of the National Health Insurance Directory has transferred 150 varieties, about half of which are drugs withdrawn by the State Drug Administration, and the rest are mainly drugs with low clinical value, obvious abuse and better substitution 　　The opinion draft issued by the State Medical Insurance Administration further clarifies the specific conditions for the transfer of drugs from the medical insurance catalogue: drugs in the Drug Catalog, if there are one of the following cases, after expert review, directly transferred out of the Drug Catalog: (1) drugs that have been revoked, revoked or cancelled by the drug regulatory authorities ; prohibited by the relevant departments from producing, selling and using drugs; (3) drugs listed by relevant departments and institutions; (4) taking into account clinical value, adverse reactions, drug economy and other factors, and the drug that is assessed as risk-outweighed by the benefits; and (5) drugs that enter the Drug Catalog through illegal means such as fraud; 　　(6) Other circumstances that should be directly transferred by the State 　　In addition, the draft also stipulates that the following drugs are not included in the Drug List: drugs that mainly tonic; drugs containing the national precious and endangered wildlife medicinal ; health drugs; Class B OTC drugs; tablets reprocessed on standard drinktablets, such as broken-walled tablets and refined tablets; preventive vaccines and contraceptives; and mainly enhanced function, treatment Drugs that have the effects of hair loss, weight loss, beauty, smoking cessation, alcohol withdrawal, etc.; diagnostic reagents, test reagents, etc., included in the treatment and treatment items; wine preparations, tea preparations, all kinds of fruit-flavoured preparations (except children's medications in special cases), oral medications and oral foaming agents (except in special cases), etc.; in violation of national laws, regulations, and other drugs that do not meet the provisions of the basic medical insurance drug administration 　　On the one hand, the policy requires the gradual digestion of local medical insurance supplementary varieties, a large number of drugs will lose local reimbursement qualifications, on the other hand, is the normal adjustment of the national health insurance catalog, many drugs that do not meet the relevant value orientation will be directly transferred out of the national health insurance 　　In the context of the overall more dynamic health insurance adjustment, the relevant pharmaceutical companies must be closer to the value of medical insurance, pay attention to the clinical safety and effectiveness of drug use, and further improve the cost-effective products 　　Attached: The drug that was transferred out of Guangxi's "Drug Catalog" part of the Western medicine part of the traditional Chinese medicine